BioSpace News Archive

Allen Technologies, the leader in interactive patient engagement solutions for 40 years, announced today that Val Verde Regional Medical Center has chosen Allen Technologies to deploy its interactive patient engagement solutions on smart TVs across 100 patient locations.

After 3 years as the official distributor of JCRB cell lines in North America, Sekisui XenoTech has expanded its agreement with the National Institute of Biomedical Innovation to include distribution to Europe.

AWAK Technologies (AWAK), a pioneering medical technology company focused on dialysis using regeneration technology for end-stage renal disease, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to its AWAK Peritoneal Dialysis (AWAK PD) device, a wearable and ultra-portable PD system that incorporates AWAK’s patented sorbent technology.

Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that its Board of Directors has approved a share purchase program, which would involve the purchase of up to $100 million of the Company’s outstanding ordinary shares over a five-year period.

The world’s deadliest major cancer – pancreatic cancer – still has a five-year survival rate of just 9 percent, according to the Cancer Facts & Figures report released today by the American Cancer Society (ACS), and it is projected to become the second leading cause of cancer-related death in the United States as early as next year.

Amryt, a revenue generating orphan drug company focused on acquiring, developing and commercialising products that help improve the lives of patients where there is a high unmet medical need, today announces positive results from two pre-clinical studies which support the development of its novel non-viral gene therapy, AP103, as a potentially disease-modifying therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (“RDEB”), a subset of Epidermolysis Bullosa (“EB”).

ImmunoGen, Inc. today announced the sale of its residual rights to receive royalty payments on commercial sales of Kadcyla® (ado-trastuzumab emtansine) to OMERS

Highly-anticipated medical device in the compact form of a wrist watch now available for retail sale in the U.S. at OmronHealthcare.com, pairs with new insights-driven mobile application

Systems Oncology today announced that Dr. Spyro Mousses, Chief Executive Officer, will present their rapidly growing pipeline of innovative oncology programs discovered with their ExpansiveAI platform, during the 37th annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Cellular Biomedicine Group Inc. today announces the initiation of patient recruitment to support the study of anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China.